DE69835526D1 - Östrogenrezeptor - Google Patents

Östrogenrezeptor

Info

Publication number
DE69835526D1
DE69835526D1 DE69835526T DE69835526T DE69835526D1 DE 69835526 D1 DE69835526 D1 DE 69835526D1 DE 69835526 T DE69835526 T DE 69835526T DE 69835526 T DE69835526 T DE 69835526T DE 69835526 D1 DE69835526 D1 DE 69835526D1
Authority
DE
Germany
Prior art keywords
estrogen receptor
relates
ligands
receptor
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835526T
Other languages
English (en)
Other versions
DE69835526T2 (de
Inventor
Hilary Wilkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9722884.5A external-priority patent/GB9722884D0/en
Priority claimed from GBGB9806032.0A external-priority patent/GB9806032D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69835526D1 publication Critical patent/DE69835526D1/de
Application granted granted Critical
Publication of DE69835526T2 publication Critical patent/DE69835526T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
DE69835526T 1997-09-08 1998-09-04 Östrogenrezeptor Expired - Lifetime DE69835526T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5827197P 1997-09-08 1997-09-08
US58271P 1997-09-08
US6052097P 1997-09-30 1997-09-30
US60520P 1997-09-30
GB9722884 1997-10-30
GBGB9722884.5A GB9722884D0 (en) 1997-10-30 1997-10-30 Estrogen receptor
GBGB9806032.0A GB9806032D0 (en) 1998-03-20 1998-03-20 Estrogen receptor
GB9806032 1998-03-20
PCT/US1998/018577 WO1999012961A1 (en) 1997-09-08 1998-09-04 Estrogen receptor

Publications (2)

Publication Number Publication Date
DE69835526D1 true DE69835526D1 (de) 2006-09-21
DE69835526T2 DE69835526T2 (de) 2007-08-02

Family

ID=27451718

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835526T Expired - Lifetime DE69835526T2 (de) 1997-09-08 1998-09-04 Östrogenrezeptor

Country Status (8)

Country Link
EP (1) EP1012177B1 (de)
JP (1) JP4307708B2 (de)
AT (1) ATE335820T1 (de)
AU (1) AU747049B2 (de)
CA (1) CA2302629C (de)
DE (1) DE69835526T2 (de)
ES (1) ES2268789T3 (de)
WO (1) WO1999012961A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157568B1 (en) 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
IT1313552B1 (it) * 1999-06-29 2002-09-09 European Molecular Biology Lab Embl Isoforme del recettore alfa degli estrogeni umano

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE183516T1 (de) * 1995-09-08 1999-09-15 Karobio Ab Waisen-rezeptor
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
US7157568B1 (en) * 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
JP2001514843A (ja) * 1997-09-04 2001-09-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＡＰ１部位でのエストロゲンレセプターＥＲαおよびＥＲβの弁別的なリガンド活性化

Also Published As

Publication number Publication date
WO1999012961A8 (en) 1999-05-27
EP1012177A1 (de) 2000-06-28
EP1012177A4 (de) 2004-10-06
ES2268789T3 (es) 2007-03-16
JP2001525319A (ja) 2001-12-11
JP4307708B2 (ja) 2009-08-05
EP1012177B1 (de) 2006-08-09
AU9305298A (en) 1999-03-29
CA2302629A1 (en) 1999-03-18
CA2302629C (en) 2001-02-20
ATE335820T1 (de) 2006-09-15
AU747049B2 (en) 2002-05-09
DE69835526T2 (de) 2007-08-02
WO1999012961A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
ATE285798T1 (de) Radioaktive embolisierende zusammensetzungen
MXPA04001940A (es) Tratamiento para desordenes del sistema nervioso central.
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
WO2002089738A3 (en) Proteomimetic compounds and methods
DE69528829D1 (de) Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
IL140419A0 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
AP9801269A0 (en) Prostaglandin agonists.
AU1618000A (en) Use of radioligands to screen inhibitors of amyloid-beta peptide production
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
DE69838882D1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
GB9712966D0 (en) Novel chalcones
DE60025639D1 (de) Substituierte diazepan
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE335820T1 (de) Östrogenrezeptor
WO2000021550A3 (en) Methods and compositions for treating neurodegenerative diseases
DE60201892D1 (en) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
MXPA02001204A (es) Compuestos calciliticos.
ATE247101T1 (de) Benzothiophenderivate, zwischenprodukte, verfahren, zubereitungen und methoden
AU7525398A (en) Inhibitors for urokinase receptor
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
PL331321A1 (en) Treatment pf psychotic disorders
DE50004792D1 (de) Mit phosphonsäureester-, phosphonsäure- oder carbaboran-funktionen substituierte oligomere und die entsprechenden pna-monomere
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
DE60123105D1 (de) Verfahren zur Herstellung von 4'-O-substituierten 4'-Demethyl-1 desoxypodophyllotoxinderivaten und geometrischen Isomeren davon ,und Antikrebspräparat, das diese enthält

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US

8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US